Multiple endocrine neoplasia type 2 cost-effectiveness of therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
Cost-effectiveness of therapy of multiple endocrine neoplasia type 2 include targeted therapy, | Cost-effectiveness of therapy of multiple endocrine neoplasia type 2 include targeted therapy, prophylactic [[thyroidectomy]] and restricted molecular screening. | ||
==Cost-Effectiveness of Therapy== | ==Cost-Effectiveness of Therapy== | ||
===Methods for cost effectiveness of the therapy=== | ===Methods for cost effectiveness of the therapy=== | ||
* Molecular screening of RET gene limiting to exon 10,11 and 16 is an effective way of reducing the cost of management of thyroidectomy. | * Molecular screening of ''RET'' [[gene]] limiting to [[exon]] 10,11 and 16 is an effective way of reducing the cost of management of [[thyroidectomy]]. | ||
* For diagnosis of multiple endocrine neoplasia type 2B, investigation of exon 16 is adequate and this further is a cost effective method.<ref name="pmid19443294">{{cite journal| author=Chang CF, Yang WS, Su YN, Wu IL, Chang TC| title=Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan. | journal=J Formos Med Assoc | year= 2009 | volume= 108 | issue= 5 | pages= 402-8 | pmid=19443294 | doi=10.1016/S0929-6646(09)60084-X | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19443294 }} </ref> | * For [[diagnosis]] of multiple endocrine neoplasia type 2B, investigation of [[exon]] 16 is adequate and this further is a cost effective method.<ref name="pmid19443294">{{cite journal| author=Chang CF, Yang WS, Su YN, Wu IL, Chang TC| title=Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan. | journal=J Formos Med Assoc | year= 2009 | volume= 108 | issue= 5 | pages= 402-8 | pmid=19443294 | doi=10.1016/S0929-6646(09)60084-X | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19443294 }} </ref> | ||
* Prophylactic thyroidectomy of patients screened positive for RET gene is a cost effective way of management of thyroidectomy.<ref name="pmid11981210">{{cite journal| author=Cohen MS, Phay JE, Albinson C, DeBenedetti MK, Skinner MA, Lairmore TC et al.| title=Gastrointestinal manifestations of multiple endocrine neoplasia type 2. | journal=Ann Surg | year= 2002 | volume= 235 | issue= 5 | pages= 648-54; discussion 654-5 | pmid=11981210 | doi= | pmc=PMC1422490 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11981210 }} </ref> | * Prophylactic [[thyroidectomy]] of patients screened positive for ''RET'' [[gene]] is a cost effective way of management of [[thyroidectomy]].<ref name="pmid11981210">{{cite journal| author=Cohen MS, Phay JE, Albinson C, DeBenedetti MK, Skinner MA, Lairmore TC et al.| title=Gastrointestinal manifestations of multiple endocrine neoplasia type 2. | journal=Ann Surg | year= 2002 | volume= 235 | issue= 5 | pages= 648-54; discussion 654-5 | pmid=11981210 | doi= | pmc=PMC1422490 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11981210 }} </ref> | ||
* Targeted therapy of multiple endocrine neoplasia type 2B yields lower costs that the present management of multiple endocrine neoplasia type 2.<ref name=Cost-effectiveness of targeted and population based screening strategies for multiple endocrine neoplasia type 2B>{{cite web | title = CREST Cost-effectiveness of targeted and population based screening strategies for multiple endocrine neoplasia type 2B| url = http://www.crest.uts.edu.au/pdfs/MEN2B_final.pdf }}</ref> | * Targeted therapy of multiple endocrine neoplasia type 2B yields lower costs that the present management of multiple endocrine neoplasia type 2.<ref name=Cost-effectiveness of targeted and population based screening strategies for multiple endocrine neoplasia type 2B>{{cite web | title = CREST Cost-effectiveness of targeted and population based screening strategies for multiple endocrine neoplasia type 2B| url = http://www.crest.uts.edu.au/pdfs/MEN2B_final.pdf }}</ref> | ||
==References== | ==References== |
Revision as of 00:17, 29 September 2015
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 cost-effectiveness of therapy |
FDA on Multiple endocrine neoplasia type 2 cost-effectiveness of therapy |
CDC on Multiple endocrine neoplasia type 2 cost-effectiveness of therapy |
Multiple endocrine neoplasia type 2 cost-effectiveness of therapy in the news |
Blogs on Multiple endocrine neoplasia type 2 cost-effectiveness of therapy |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Cost-effectiveness of therapy of multiple endocrine neoplasia type 2 include targeted therapy, prophylactic thyroidectomy and restricted molecular screening.
Cost-Effectiveness of Therapy
Methods for cost effectiveness of the therapy
- Molecular screening of RET gene limiting to exon 10,11 and 16 is an effective way of reducing the cost of management of thyroidectomy.
- For diagnosis of multiple endocrine neoplasia type 2B, investigation of exon 16 is adequate and this further is a cost effective method.[1]
- Prophylactic thyroidectomy of patients screened positive for RET gene is a cost effective way of management of thyroidectomy.[2]
- Targeted therapy of multiple endocrine neoplasia type 2B yields lower costs that the present management of multiple endocrine neoplasia type 2.
References
- ↑ Chang CF, Yang WS, Su YN, Wu IL, Chang TC (2009). "Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan". J Formos Med Assoc. 108 (5): 402–8. doi:10.1016/S0929-6646(09)60084-X. PMID 19443294.
- ↑ Cohen MS, Phay JE, Albinson C, DeBenedetti MK, Skinner MA, Lairmore TC; et al. (2002). "Gastrointestinal manifestations of multiple endocrine neoplasia type 2". Ann Surg. 235 (5): 648–54, discussion 654-5. PMC 1422490. PMID 11981210.